* Treatment with obesity drug Saxenda for three years reduced risk of developing type 2 diabetes compared with placebo
COPENHAGEN, May 20 (Reuters) - Novo Nordisk on Wednesday rejected claims by Baxter International that its drug used substances developed by the U.S. rival, following the launch this week of a U.S. investigation into possible patent infringement.
COPENHAGEN, May 20 (Reuters) - Novo Nordisk said on Wednesday it rejected claims by U.S. rival Baxter International that it had infringed patents on drugs to treat the bleeding disorder haemophilia,...
* Says Janssen Biotech Inc will acquire licence to further develop and commercialise a clinical programme focused on therapy within auto-immune diseases
COPENHAGEN, May 18 (Reuters) - Novo Nordisk is looking into recent clinical trial data that show its diabetes drug Victoza has potential as a treatment for fatty liver disease, a hot area for pharmaceutical development.
COPENHAGEN, May 12 (Reuters) - IT services business NNIT , a unit of drugmaker Novo Nordisk until its March listing, reported a rise in operating profit in its first earnings report as a publicly listed company on the Copenhagen stock exchange.
* Says new data demonstrated Saxenda provides benefits beyond weight loss
the new CEO effective mid-May buoys the outlook for the firm. Schultz brings an excellent track record as COO for Novo Nordisk , a company with exemplary operational performance and commitment to generating shareholder value. We plan to maintain
COPENHAGEN, May 6 (Reuters) - Drugmaker Lundbeck named Kaare Schultz as its new chief a week after the respected executive quit Novo Nordisk , a coup for the struggling smaller firm that sent its...
COPENHAGEN, May 6 (Reuters) - Danish drug company Lundbeck named Kaare Schultz as its new chief on Wednesday just a week after the respected industry executive quit Novo Nordisk when that firm's boss decided to stay on.